ribupatide vs Tirzepatide (Mounjaro)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06649344 · Phase 3 · completed

This phase 3 trial randomly assigned 884 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to once-weekly ribupatide 4 mg, ribupatide 2 mg or semaglutide 1 mg, with open-label treatment. The primary measure was HbA1c change at week 36, tested for non-inferiority against semaglutide. The company reports that both doses were non-inferior (HbA1c -2.78% and -2.34% against -2.29%) and that 4 mg was statistically superior, so the result is met. The margin and confidence intervals were not published, and the figures come from the company's own release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07060456 (registry estimate)

Reported efficacy

Change in HbA1c (from baseline to 36 weeks treatment): Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo (met)

Result source: NCT06650007

Tirzepatide (Mounjaro)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT03730662 · Phase 3 · completed

The study randomized 2,002 participants to tirzepatide or active insulin glargine control, but treatment was open-label rather than blinded. The primary endpoint was change in HbA1c, a laboratory surrogate rather than a hard clinical outcome; although the primary comparisons were statistically significant in favor of tirzepatide, this supports a moderate evidence grade.

Next expected readout: December 2027 · NCT06657209 (registry estimate)

Reported efficacy

Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579 (met)

Result source: NCT04255433

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointribupatideTirzepatide (Mounjaro)
HbA1c, change—Not posted · NCT06650007-2.1% vs 0.0%−2.1 vs placebo15 mg · wk 40 · n 116NCT03954834
50 other results
  • -2.6% vs -0.9% 15 mg · wk 40 · n 117 · Phase 3 · primary NCT04039503
  • -2.0% vs -0.8% 15 mg · wk 40 · n 48 · Phase 3 · primary NCT05963022
  • -1.9% vs 0.0% 10 mg · wk 40 · n 118 · Phase 3 · primary NCT03954834
  • -2.6% vs -0.9% 10 mg · wk 40 · n 113 · Phase 3 · primary NCT04039503
  • -1.8% vs -0.8% 10 mg · wk 40 · n 44 · Phase 3 · primary NCT05963022
  • -1.9% vs 0.0% 5 mg · wk 40 · n 121 · Phase 3 · primary NCT03954834
  • -2.2% vs -0.8% 5 mg · wk 40 · n 52 · Phase 3 · primary NCT05963022
  • -2.6% vs -1.4% 15 mg once weekly · wk 52 · n 291 · Phase 3 · primary NCT03730662
  • -2.4% vs -1.3% 15 mg · wk 52 · n 294 · Phase 3 · primary NCT03882970
  • -2.8% vs -1.3% 15 mg · wk 52 · n 159 · Phase 3 · primary NCT03861052
  • -2.5% vs -1.9% 15 mg weekly · wk 40 · n 464 · Phase 3 · primary NCT03987919
  • -2.5% vs -0.9% 15 mg · wk 40 · n 193 · Phase 3 · primary NCT04093752
  • -2.4% vs -1.4% 10 mg once weekly · wk 52 · n 289 · Phase 3 · primary NCT03730662
  • -2.2% vs -1.3% 10 mg · wk 52 · n 291 · Phase 3 · primary NCT03882970
  • -2.5% vs -1.3% 10 mg · wk 52 · n 156 · Phase 3 · primary NCT03861052
  • -2.4% vs -1.9% 10 mg weekly · wk 40 · n 459 · Phase 3 · primary NCT03987919
  • -2.4% vs -0.9% 10 mg · wk 40 · n 194 · Phase 3 · primary NCT04093752
  • -2.4% vs -1.3% 5 mg · wk 52 · n 158 · Phase 3 · primary NCT03861052
  • -2.2% vs -0.9% 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • -2.2% vs -0.2% 10 mg · wk 30 · n 27 · Phase 3 · secondary NCT05260021
  • -1.9% vs -0.2% 5 mg · wk 30 · n 29 · Phase 3 · secondary NCT05260021
  • -1.7% vs -0.9% MTD · wk 156 · n 6586 · Phase 3 · secondary NCT04255433
  • -2.5% vs -1.2% 15 mg · wk 52 · n 233 · Phase 3 · secondary NCT04537923
  • -2.3% vs -1.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT04537923
  • -2.2% vs -1.4% 5 mg once weekly · wk 52 · n 283 · Phase 3 · secondary NCT03730662
  • -1.9% vs -1.3% 5 mg · wk 52 · n 312 · Phase 3 · secondary NCT03882970
  • -2.0% vs -1.2% 5 mg · wk 52 · n 241 · Phase 3 · secondary NCT04537923
  • -2.1% vs -1.9% 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • -2.2% vs -0.9% 5 mg · wk 40 · n 211 · Phase 3 · secondary NCT04093752
  • -1.9% vs -0.1% 15 mg · wk 26 · n 44 · Phase 2 · primary NCT03131687
  • -2% vs 0.2% wk 12 · n 23 · Phase 2 · primary NCT03311724
  • -1.8% vs 0.2% wk 12 · n 26 · Phase 2 · primary NCT03311724
  • -1.9% vs -0.1% 10 mg · wk 26 · n 47 · Phase 2 · primary NCT03131687
  • -1.7% vs -0.1% 5 mg · wk 26 · n 52 · Phase 2 · primary NCT03131687
  • -1.7% vs 0.2% wk 12 · n 27 · Phase 2 · primary NCT03311724
  • -1.1% vs -0.1% 1 mg · wk 26 · n 45 · Phase 2 · primary NCT03131687
  • -1.6% vs -0.7% 15 mg or MTD · wk 40 · n 114 · Phase 4 · primary NCT05564039
  • 2.0% vs 0.3% 15 mg · wk 28 · n 41 · Phase 1 · secondary NCT03951753
  • -2.4% vs 0.1% 15 mg · wk 26 · n 35 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 15 mg · wk 12 · n 48 · Phase 2 · secondary NCT03131687
  • -2.1% vs -0.1% 15 mg · wk 12 · n 36 · Phase 2 · secondary NCT03131687
  • -2% vs 0.1% 10 mg · wk 26 · n 43 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 10 mg · wk 12 · n 48 · Phase 2 · secondary NCT03131687
  • -2% vs -0.1% 10 mg · wk 12 · n 47 · Phase 2 · secondary NCT03131687
  • -1.6% vs 0.1% 5 mg · wk 26 · n 47 · Phase 2 · secondary NCT03131687
  • -1.5% vs -0.1% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT03131687
  • -0.7% vs 0.1% 1 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -0.9% vs -0.1% 1 mg · wk 12 · n 45 · Phase 2 · secondary NCT03131687
  • -0.9% vs -0.1% 1 mg · wk 12 · n 44 · Phase 2 · secondary NCT03131687
Body weight, change (kg)—Not posted · NCT06650007-9.5 vs -0.7−8.8 vs placebo15 mg · wk 40 · n 116NCT03954834
37 other results
  • -10.9 vs 1.7 15 mg · wk 40 · n 117 · Phase 3 · secondary NCT04039503
  • -8.7 vs -1.3 15 mg · wk 40 · n 48 · Phase 3 · secondary NCT05963022
  • -4.3 vs 1.7 15 mg · wk 40 · n 55 · Phase 3 · secondary NCT05691712
  • -7.8 vs -0.7 10 mg · wk 40 · n 118 · Phase 3 · secondary NCT03954834
  • -8.2 vs 1.7 10 mg · wk 40 · n 113 · Phase 3 · secondary NCT04039503
  • -5.5 vs -1.3 10 mg · wk 40 · n 46 · Phase 3 · secondary NCT05963022
  • -4.8 vs 1.7 10 mg · wk 40 · n 57 · Phase 3 · secondary NCT05691712
  • -7 vs -0.7 5 mg · wk 40 · n 121 · Phase 3 · secondary NCT03954834
  • -6.2 vs 1.7 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • -6.1 vs -1.3 5 mg · wk 40 · n 52 · Phase 3 · secondary NCT05963022
  • -2.7 vs 1.7 5 mg · wk 40 · n 62 · Phase 3 · secondary NCT05691712
  • -11.7 vs 1.9 15 mg once weekly · wk 52 · n 291 · Phase 3 · secondary NCT03730662
  • -12.9 vs 2.3 15 mg · wk 52 · n 295 · Phase 3 · secondary NCT03882970
  • -12 vs 3.8 15 mg · wk 52 · n 233 · Phase 3 · secondary NCT04537923
  • -10.7 vs -0.5 15 mg · wk 52 · n 159 · Phase 3 · secondary NCT03861052
  • -12.4 vs -6.2 15 mg weekly · wk 40 · n 464 · Phase 3 · secondary NCT03987919
  • -7.2 vs 1.5 15 mg · wk 40 · n 193 · Phase 3 · secondary NCT04093752
  • -9.5 vs 1.9 10 mg once weekly · wk 52 · n 288 · Phase 3 · secondary NCT03730662
  • -10.7 vs 2.3 10 mg · wk 52 · n 291 · Phase 3 · secondary NCT03882970
  • -9.9 vs 3.8 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT04537923
  • -8.5 vs -0.5 10 mg · wk 52 · n 156 · Phase 3 · secondary NCT03861052
  • -10.3 vs -6.2 10 mg weekly · wk 40 · n 459 · Phase 3 · secondary NCT03987919
  • -7 vs 1.5 10 mg · wk 40 · n 194 · Phase 3 · secondary NCT04093752
  • -7.1 vs 1.9 5 mg once weekly · wk 52 · n 285 · Phase 3 · secondary NCT03730662
  • -7.5 vs 2.3 5 mg · wk 52 · n 310 · Phase 3 · secondary NCT03882970
  • -6.9 vs 3.8 5 mg · wk 52 · n 241 · Phase 3 · secondary NCT04537923
  • -5.8 vs -0.5 5 mg · wk 52 · n 158 · Phase 3 · secondary NCT03861052
  • -7.8 vs -6.2 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • -5 vs 1.5 5 mg · wk 40 · n 211 · Phase 3 · secondary NCT04093752
  • -11.3 vs -0.4 15 mg · wk 26 · n 35 · Phase 2 · secondary NCT03131687
  • -5.5 vs -0.5 wk 12 · n 23 · Phase 2 · secondary NCT03311724
  • -5.7 vs -0.5 wk 12 · n 26 · Phase 2 · secondary NCT03311724
  • -8.7 vs -0.4 10 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -4.8 vs -0.4 5 mg · wk 26 · n 48 · Phase 2 · secondary NCT03131687
  • -5.3 vs -0.5 wk 12 · n 27 · Phase 2 · secondary NCT03311724
  • -0.9 vs -0.4 1 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -11 vs -3.6 15 mg or MTD · wk 40 · n 123 · Phase 4 · secondary NCT05564039
HbA1c below 7%—Not posted · NCT0665000787.9% vs 19.6%+68.3 vs placebo15 mg · wk 40 · n 116NCT03954834
36 other results
  • 94.0% vs 33.9% 15 mg · wk 40 · n 117 · Phase 3 · secondary NCT04039503
  • 83.3% vs 38.3% 15 mg · wk 40 · n 48 · Phase 3 · secondary NCT05963022
  • 91.5% vs 19.6% 10 mg · wk 40 · n 118 · Phase 3 · secondary NCT03954834
  • 97.3% vs 33.9% 10 mg · wk 40 · n 113 · Phase 3 · secondary NCT04039503
  • 86.4% vs 38.3% 10 mg · wk 40 · n 44 · Phase 3 · secondary NCT05963022
  • 86.8% vs 19.6% 5 mg · wk 40 · n 121 · Phase 3 · secondary NCT03954834
  • 93.0% vs 33.9% 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • 84.5% vs 37.4% 10 mg · wk 30 · n 33 · Phase 3 · secondary NCT05260021
  • 90.4% vs 38.3% 5 mg · wk 40 · n 52 · Phase 3 · secondary NCT05963022
  • 79.6% vs 37.4% 5 mg · wk 30 · n 32 · Phase 3 · secondary NCT05260021
  • 90.7% vs 50.7% 15 mg once weekly · wk 52 · n 334 · Phase 3 · secondary NCT03730662
  • 92.6% vs 61.3% 15 mg · wk 52 · n 353 · Phase 3 · secondary NCT03882970
  • 79.9% vs 36.7% 15 mg · wk 52 · n 236 · Phase 3 · secondary NCT04537923
  • 99.4% vs 67.3% 15 mg · wk 52 · n 159 · Phase 3 · secondary NCT03861052
  • 92.2% vs 81.1% 15 mg weekly · wk 40 · n 464 · Phase 3 · secondary NCT03987919
  • 84.4% vs 23.7% 15 mg · wk 40 · n 224 · Phase 3 · secondary NCT04093752
  • 88.2% vs 50.7% 10 mg once weekly · wk 52 · n 321 · Phase 3 · secondary NCT03730662
  • 89.7% vs 61.3% 10 mg · wk 52 · n 350 · Phase 3 · secondary NCT03882970
  • 75.6% vs 36.7% 10 mg · wk 52 · n 238 · Phase 3 · secondary NCT04537923
  • 96.8% vs 67.3% 10 mg · wk 52 · n 156 · Phase 3 · secondary NCT03861052
  • 88.9% vs 81.1% 10 mg weekly · wk 40 · n 459 · Phase 3 · secondary NCT03987919
  • 86.0% vs 23.7% 10 mg · wk 40 · n 222 · Phase 3 · secondary NCT04093752
  • 81.0% vs 50.7% 5 mg once weekly · wk 52 · n 326 · Phase 3 · secondary NCT03730662
  • 82.4% vs 61.3% 5 mg · wk 52 · n 353 · Phase 3 · secondary NCT03882970
  • 61.0% vs 36.7% 5 mg · wk 52 · n 242 · Phase 3 · secondary NCT04537923
  • 93.7% vs 67.3% 5 mg · wk 52 · n 158 · Phase 3 · secondary NCT03861052
  • 85.5% vs 81.1% 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • 75.4% vs 23.7% 5 mg · wk 40 · n 228 · Phase 3 · secondary NCT04093752
  • 77.4% vs 11.8% 15 mg · wk 26 · n 53 · Phase 2 · secondary NCT03131687
  • 87% vs 10% wk 12 · n 23 · Phase 2 · secondary NCT03311724
  • 84.6% vs 10% wk 12 · n 26 · Phase 2 · secondary NCT03311724
  • 90% vs 11.8% 10 mg · wk 26 · n 50 · Phase 2 · secondary NCT03131687
  • 69.1% vs 11.8% 5 mg · wk 26 · n 55 · Phase 2 · secondary NCT03131687
  • 74.1% vs 10% wk 12 · n 27 · Phase 2 · secondary NCT03311724
  • 32.7% vs 11.8% 1 mg · wk 26 · n 52 · Phase 2 · secondary NCT03131687
  • 84.2% vs 52.4% 15 mg or MTD · wk 40 · n 114 · Phase 4 · secondary NCT05564039
Fasting plasma glucose, change—Not posted · NCT06650007—Not posted · NCT06534411
3-point MACE (% with event)—Not posted · NCT0665000712.2% vs 13.1%vs DulaglutideMTD · wk 259 · n 6586NCT04255433

HbA1c, change

ribupatide
—Not posted · NCT06650007
Tirzepatide (Mounjaro)
-2.1% vs 0.0%−2.1 vs placebo15 mg · wk 40 · n 116NCT03954834
50 other results
  • -2.6% vs -0.9% 15 mg · wk 40 · n 117 · Phase 3 · primary NCT04039503
  • -2.0% vs -0.8% 15 mg · wk 40 · n 48 · Phase 3 · primary NCT05963022
  • -1.9% vs 0.0% 10 mg · wk 40 · n 118 · Phase 3 · primary NCT03954834
  • -2.6% vs -0.9% 10 mg · wk 40 · n 113 · Phase 3 · primary NCT04039503
  • -1.8% vs -0.8% 10 mg · wk 40 · n 44 · Phase 3 · primary NCT05963022
  • -1.9% vs 0.0% 5 mg · wk 40 · n 121 · Phase 3 · primary NCT03954834
  • -2.2% vs -0.8% 5 mg · wk 40 · n 52 · Phase 3 · primary NCT05963022
  • -2.6% vs -1.4% 15 mg once weekly · wk 52 · n 291 · Phase 3 · primary NCT03730662
  • -2.4% vs -1.3% 15 mg · wk 52 · n 294 · Phase 3 · primary NCT03882970
  • -2.8% vs -1.3% 15 mg · wk 52 · n 159 · Phase 3 · primary NCT03861052
  • -2.5% vs -1.9% 15 mg weekly · wk 40 · n 464 · Phase 3 · primary NCT03987919
  • -2.5% vs -0.9% 15 mg · wk 40 · n 193 · Phase 3 · primary NCT04093752
  • -2.4% vs -1.4% 10 mg once weekly · wk 52 · n 289 · Phase 3 · primary NCT03730662
  • -2.2% vs -1.3% 10 mg · wk 52 · n 291 · Phase 3 · primary NCT03882970
  • -2.5% vs -1.3% 10 mg · wk 52 · n 156 · Phase 3 · primary NCT03861052
  • -2.4% vs -1.9% 10 mg weekly · wk 40 · n 459 · Phase 3 · primary NCT03987919
  • -2.4% vs -0.9% 10 mg · wk 40 · n 194 · Phase 3 · primary NCT04093752
  • -2.4% vs -1.3% 5 mg · wk 52 · n 158 · Phase 3 · primary NCT03861052
  • -2.2% vs -0.9% 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • -2.2% vs -0.2% 10 mg · wk 30 · n 27 · Phase 3 · secondary NCT05260021
  • -1.9% vs -0.2% 5 mg · wk 30 · n 29 · Phase 3 · secondary NCT05260021
  • -1.7% vs -0.9% MTD · wk 156 · n 6586 · Phase 3 · secondary NCT04255433
  • -2.5% vs -1.2% 15 mg · wk 52 · n 233 · Phase 3 · secondary NCT04537923
  • -2.3% vs -1.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT04537923
  • -2.2% vs -1.4% 5 mg once weekly · wk 52 · n 283 · Phase 3 · secondary NCT03730662
  • -1.9% vs -1.3% 5 mg · wk 52 · n 312 · Phase 3 · secondary NCT03882970
  • -2.0% vs -1.2% 5 mg · wk 52 · n 241 · Phase 3 · secondary NCT04537923
  • -2.1% vs -1.9% 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • -2.2% vs -0.9% 5 mg · wk 40 · n 211 · Phase 3 · secondary NCT04093752
  • -1.9% vs -0.1% 15 mg · wk 26 · n 44 · Phase 2 · primary NCT03131687
  • -2% vs 0.2% wk 12 · n 23 · Phase 2 · primary NCT03311724
  • -1.8% vs 0.2% wk 12 · n 26 · Phase 2 · primary NCT03311724
  • -1.9% vs -0.1% 10 mg · wk 26 · n 47 · Phase 2 · primary NCT03131687
  • -1.7% vs -0.1% 5 mg · wk 26 · n 52 · Phase 2 · primary NCT03131687
  • -1.7% vs 0.2% wk 12 · n 27 · Phase 2 · primary NCT03311724
  • -1.1% vs -0.1% 1 mg · wk 26 · n 45 · Phase 2 · primary NCT03131687
  • -1.6% vs -0.7% 15 mg or MTD · wk 40 · n 114 · Phase 4 · primary NCT05564039
  • 2.0% vs 0.3% 15 mg · wk 28 · n 41 · Phase 1 · secondary NCT03951753
  • -2.4% vs 0.1% 15 mg · wk 26 · n 35 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 15 mg · wk 12 · n 48 · Phase 2 · secondary NCT03131687
  • -2.1% vs -0.1% 15 mg · wk 12 · n 36 · Phase 2 · secondary NCT03131687
  • -2% vs 0.1% 10 mg · wk 26 · n 43 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 10 mg · wk 12 · n 48 · Phase 2 · secondary NCT03131687
  • -2% vs -0.1% 10 mg · wk 12 · n 47 · Phase 2 · secondary NCT03131687
  • -1.6% vs 0.1% 5 mg · wk 26 · n 47 · Phase 2 · secondary NCT03131687
  • -1.5% vs -0.1% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT03131687
  • -1.7% vs -0.1% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT03131687
  • -0.7% vs 0.1% 1 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -0.9% vs -0.1% 1 mg · wk 12 · n 45 · Phase 2 · secondary NCT03131687
  • -0.9% vs -0.1% 1 mg · wk 12 · n 44 · Phase 2 · secondary NCT03131687

Body weight, change (kg)

ribupatide
—Not posted · NCT06650007
Tirzepatide (Mounjaro)
-9.5 vs -0.7−8.8 vs placebo15 mg · wk 40 · n 116NCT03954834
37 other results
  • -10.9 vs 1.7 15 mg · wk 40 · n 117 · Phase 3 · secondary NCT04039503
  • -8.7 vs -1.3 15 mg · wk 40 · n 48 · Phase 3 · secondary NCT05963022
  • -4.3 vs 1.7 15 mg · wk 40 · n 55 · Phase 3 · secondary NCT05691712
  • -7.8 vs -0.7 10 mg · wk 40 · n 118 · Phase 3 · secondary NCT03954834
  • -8.2 vs 1.7 10 mg · wk 40 · n 113 · Phase 3 · secondary NCT04039503
  • -5.5 vs -1.3 10 mg · wk 40 · n 46 · Phase 3 · secondary NCT05963022
  • -4.8 vs 1.7 10 mg · wk 40 · n 57 · Phase 3 · secondary NCT05691712
  • -7 vs -0.7 5 mg · wk 40 · n 121 · Phase 3 · secondary NCT03954834
  • -6.2 vs 1.7 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • -6.1 vs -1.3 5 mg · wk 40 · n 52 · Phase 3 · secondary NCT05963022
  • -2.7 vs 1.7 5 mg · wk 40 · n 62 · Phase 3 · secondary NCT05691712
  • -11.7 vs 1.9 15 mg once weekly · wk 52 · n 291 · Phase 3 · secondary NCT03730662
  • -12.9 vs 2.3 15 mg · wk 52 · n 295 · Phase 3 · secondary NCT03882970
  • -12 vs 3.8 15 mg · wk 52 · n 233 · Phase 3 · secondary NCT04537923
  • -10.7 vs -0.5 15 mg · wk 52 · n 159 · Phase 3 · secondary NCT03861052
  • -12.4 vs -6.2 15 mg weekly · wk 40 · n 464 · Phase 3 · secondary NCT03987919
  • -7.2 vs 1.5 15 mg · wk 40 · n 193 · Phase 3 · secondary NCT04093752
  • -9.5 vs 1.9 10 mg once weekly · wk 52 · n 288 · Phase 3 · secondary NCT03730662
  • -10.7 vs 2.3 10 mg · wk 52 · n 291 · Phase 3 · secondary NCT03882970
  • -9.9 vs 3.8 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT04537923
  • -8.5 vs -0.5 10 mg · wk 52 · n 156 · Phase 3 · secondary NCT03861052
  • -10.3 vs -6.2 10 mg weekly · wk 40 · n 459 · Phase 3 · secondary NCT03987919
  • -7 vs 1.5 10 mg · wk 40 · n 194 · Phase 3 · secondary NCT04093752
  • -7.1 vs 1.9 5 mg once weekly · wk 52 · n 285 · Phase 3 · secondary NCT03730662
  • -7.5 vs 2.3 5 mg · wk 52 · n 310 · Phase 3 · secondary NCT03882970
  • -6.9 vs 3.8 5 mg · wk 52 · n 241 · Phase 3 · secondary NCT04537923
  • -5.8 vs -0.5 5 mg · wk 52 · n 158 · Phase 3 · secondary NCT03861052
  • -7.8 vs -6.2 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • -5 vs 1.5 5 mg · wk 40 · n 211 · Phase 3 · secondary NCT04093752
  • -11.3 vs -0.4 15 mg · wk 26 · n 35 · Phase 2 · secondary NCT03131687
  • -5.5 vs -0.5 wk 12 · n 23 · Phase 2 · secondary NCT03311724
  • -5.7 vs -0.5 wk 12 · n 26 · Phase 2 · secondary NCT03311724
  • -8.7 vs -0.4 10 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -4.8 vs -0.4 5 mg · wk 26 · n 48 · Phase 2 · secondary NCT03131687
  • -5.3 vs -0.5 wk 12 · n 27 · Phase 2 · secondary NCT03311724
  • -0.9 vs -0.4 1 mg · wk 26 · n 44 · Phase 2 · secondary NCT03131687
  • -11 vs -3.6 15 mg or MTD · wk 40 · n 123 · Phase 4 · secondary NCT05564039

HbA1c below 7%

ribupatide
—Not posted · NCT06650007
Tirzepatide (Mounjaro)
87.9% vs 19.6%+68.3 vs placebo15 mg · wk 40 · n 116NCT03954834
36 other results
  • 94.0% vs 33.9% 15 mg · wk 40 · n 117 · Phase 3 · secondary NCT04039503
  • 83.3% vs 38.3% 15 mg · wk 40 · n 48 · Phase 3 · secondary NCT05963022
  • 91.5% vs 19.6% 10 mg · wk 40 · n 118 · Phase 3 · secondary NCT03954834
  • 97.3% vs 33.9% 10 mg · wk 40 · n 113 · Phase 3 · secondary NCT04039503
  • 86.4% vs 38.3% 10 mg · wk 40 · n 44 · Phase 3 · secondary NCT05963022
  • 86.8% vs 19.6% 5 mg · wk 40 · n 121 · Phase 3 · secondary NCT03954834
  • 93.0% vs 33.9% 5 mg · wk 40 · n 115 · Phase 3 · secondary NCT04039503
  • 84.5% vs 37.4% 10 mg · wk 30 · n 33 · Phase 3 · secondary NCT05260021
  • 90.4% vs 38.3% 5 mg · wk 40 · n 52 · Phase 3 · secondary NCT05963022
  • 79.6% vs 37.4% 5 mg · wk 30 · n 32 · Phase 3 · secondary NCT05260021
  • 90.7% vs 50.7% 15 mg once weekly · wk 52 · n 334 · Phase 3 · secondary NCT03730662
  • 92.6% vs 61.3% 15 mg · wk 52 · n 353 · Phase 3 · secondary NCT03882970
  • 79.9% vs 36.7% 15 mg · wk 52 · n 236 · Phase 3 · secondary NCT04537923
  • 99.4% vs 67.3% 15 mg · wk 52 · n 159 · Phase 3 · secondary NCT03861052
  • 92.2% vs 81.1% 15 mg weekly · wk 40 · n 464 · Phase 3 · secondary NCT03987919
  • 84.4% vs 23.7% 15 mg · wk 40 · n 224 · Phase 3 · secondary NCT04093752
  • 88.2% vs 50.7% 10 mg once weekly · wk 52 · n 321 · Phase 3 · secondary NCT03730662
  • 89.7% vs 61.3% 10 mg · wk 52 · n 350 · Phase 3 · secondary NCT03882970
  • 75.6% vs 36.7% 10 mg · wk 52 · n 238 · Phase 3 · secondary NCT04537923
  • 96.8% vs 67.3% 10 mg · wk 52 · n 156 · Phase 3 · secondary NCT03861052
  • 88.9% vs 81.1% 10 mg weekly · wk 40 · n 459 · Phase 3 · secondary NCT03987919
  • 86.0% vs 23.7% 10 mg · wk 40 · n 222 · Phase 3 · secondary NCT04093752
  • 81.0% vs 50.7% 5 mg once weekly · wk 52 · n 326 · Phase 3 · secondary NCT03730662
  • 82.4% vs 61.3% 5 mg · wk 52 · n 353 · Phase 3 · secondary NCT03882970
  • 61.0% vs 36.7% 5 mg · wk 52 · n 242 · Phase 3 · secondary NCT04537923
  • 93.7% vs 67.3% 5 mg · wk 52 · n 158 · Phase 3 · secondary NCT03861052
  • 85.5% vs 81.1% 5 mg weekly · wk 40 · n 461 · Phase 3 · secondary NCT03987919
  • 75.4% vs 23.7% 5 mg · wk 40 · n 228 · Phase 3 · secondary NCT04093752
  • 77.4% vs 11.8% 15 mg · wk 26 · n 53 · Phase 2 · secondary NCT03131687
  • 87% vs 10% wk 12 · n 23 · Phase 2 · secondary NCT03311724
  • 84.6% vs 10% wk 12 · n 26 · Phase 2 · secondary NCT03311724
  • 90% vs 11.8% 10 mg · wk 26 · n 50 · Phase 2 · secondary NCT03131687
  • 69.1% vs 11.8% 5 mg · wk 26 · n 55 · Phase 2 · secondary NCT03131687
  • 74.1% vs 10% wk 12 · n 27 · Phase 2 · secondary NCT03311724
  • 32.7% vs 11.8% 1 mg · wk 26 · n 52 · Phase 2 · secondary NCT03131687
  • 84.2% vs 52.4% 15 mg or MTD · wk 40 · n 114 · Phase 4 · secondary NCT05564039

Fasting plasma glucose, change

ribupatide
—Not posted · NCT06650007
Tirzepatide (Mounjaro)
—Not posted · NCT06534411

3-point MACE (% with event)

ribupatide
—Not posted · NCT06650007
Tirzepatide (Mounjaro)
12.2% vs 13.1%vs DulaglutideMTD · wk 259 · n 6586NCT04255433
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ribupatide
Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met. NCT06649344 · Phase 3 · design grade: moderate · publication or press release
Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo NCT06650007 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ribupatide: 0 of 4 rows · Tirzepatide (Mounjaro): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTirzepatide (Mounjaro)
Dropout rate
2.7%15 mg once weeklya
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 65 more results
3.3%10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.4%5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.1%15 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%15 mg
NCT03954834 · Phase 3
7.4%10 mg
NCT03954834 · Phase 3
5.8%5 mg
NCT03954834 · Phase 3
5.1%15 mg weekly
NCT03987919 · Phase 3
5.8%10 mg weekly
NCT03987919 · Phase 3
4%5 mg weekly
NCT03987919 · Phase 3
5.3%15 mg
NCT03882970 · Phase 3
11.1%10 mg
NCT03882970 · Phase 3
7.2%5 mg
NCT03882970 · Phase 3
8.3%15 mg
NCT04039503 · Phase 3
3.4%10 mg
NCT04039503 · Phase 3
6%5 mg
NCT04039503 · Phase 3
—10 mg
NCT05260021 · Phase 3
—10 mg
NCT05260021 · Phase 3
—5 mg
NCT05260021 · Phase 3
—5 mg
NCT05260021 · Phase 3
—MTD
NCT04255433 · Phase 3
—15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
—5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
7.7%15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
9.8%10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
—5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
7.9%15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
7.7%10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
—5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
4.7%15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
4.2%10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
6.2%5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
12.7%15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
11.8%10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
7.4%5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
3.1%15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
4.4%10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
2.5%5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
15.1%15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
—15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
5.5%5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
17%1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
7.1%2.5, 5, 10, and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
3.6%2.5, 7.5 and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
3.4%4, 8 and 12mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
—15 mg
NCT04050553 · Phase 1 · registry result, not featured evidence
0%2.5 to 15 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
10%2.5 to 10 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
8.9%15 mg
NCT03951753 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
6.3%5 mg/10 mg/15 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
8.3%2.5 mg/5 mg/10 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
—5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—8mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—4.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—2.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—1.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—1mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.25mg
NCT02759107 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0%15 mg once weeklya
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 65 more results
0.6%10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.9%5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.4%15 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.4%10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.4%5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%15 mg
NCT03954834 · Phase 3
2.5%10 mg
NCT03954834 · Phase 3
0.8%5 mg
NCT03954834 · Phase 3
0.2%15 mg weekly
NCT03987919 · Phase 3
0.9%10 mg weekly
NCT03987919 · Phase 3
0.2%5 mg weekly
NCT03987919 · Phase 3
0.8%15 mg
NCT03882970 · Phase 3
1.9%10 mg
NCT03882970 · Phase 3
1.4%5 mg
NCT03882970 · Phase 3
1.7%15 mg
NCT04039503 · Phase 3
0%10 mg
NCT04039503 · Phase 3
2.6%5 mg
NCT04039503 · Phase 3
—10 mg
NCT05260021 · Phase 3
—10 mg
NCT05260021 · Phase 3
—5 mg
NCT05260021 · Phase 3
—5 mg
NCT05260021 · Phase 3
—MTD
NCT04255433 · Phase 3
—15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
—5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
1.9%15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
2%10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
—5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
3.2%15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
1.5%10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
—5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
0.8%15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
0.4%10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
0.8%5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
8.3%15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
8.3%10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
3%5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
1.3%15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
0.6%10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
0.6%5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
3.8%15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
—15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
1.9%10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
1.9%1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
—2.5, 5, 10, and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
—2.5, 7.5 and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
—4, 8 and 12mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
—15 mg
NCT04050553 · Phase 1 · registry result, not featured evidence
0%2.5 to 15 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
0%2.5 to 10 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
2.2%15 mg
NCT03951753 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
6.3%5 mg/10 mg/15 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
0%2.5 mg/5 mg/10 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
—5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—8mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—4.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—2.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—1.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—1mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
—0.25mg
NCT02759107 · Phase 1 · registry result, not featured evidence
Serious AEs
12.1%15 mg once weeklya
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 65 more results
16.5%10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
14.6%5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.4%15 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.5%10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.4%5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%15 mg
NCT03954834 · Phase 3
1.7%10 mg
NCT03954834 · Phase 3
4.1%5 mg
NCT03954834 · Phase 3
5.7%15 mg weekly
NCT03987919 · Phase 3
5.3%10 mg weekly
NCT03987919 · Phase 3
7%5 mg weekly
NCT03987919 · Phase 3
7.2%15 mg
NCT03882970 · Phase 3
5.6%10 mg
NCT03882970 · Phase 3
8.1%5 mg
NCT03882970 · Phase 3
7.5%15 mg
NCT04039503 · Phase 3
10.9%10 mg
NCT04039503 · Phase 3
7.8%5 mg
NCT04039503 · Phase 3
3%10 mg
NCT05260021 · Phase 3
3%10 mg
NCT05260021 · Phase 3
3.1%5 mg
NCT05260021 · Phase 3
3.1%5 mg
NCT05260021 · Phase 3
31.8%MTD
NCT04255433 · Phase 3
7.2%15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
0.7%5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
5.8%15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
11.8%10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
9.6%5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
12.7%15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
7.7%10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
12.3%5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
7.2%15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
6.7%10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
8.2%5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
6.6%15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
6.1%10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
6.5%5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
4.4%15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
6.3%10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
5%5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
—15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
3.8%15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
5.9%10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
1.8%5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
3.8%1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
0%2.5, 5, 10, and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
0%2.5, 7.5 and 15mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
3.4%4, 8 and 12mg Tirzepatide
NCT03311724 · Phase 2 · registry result, not featured evidence
10.3%15 mg
NCT04050553 · Phase 1 · registry result, not featured evidence
0%2.5 to 15 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
0%2.5 to 10 mg
NCT04235959 · Phase 1 · registry result, not featured evidence
2.2%15 mg
NCT03951753 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
0%5 mg/10 mg/15 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
0%2.5 mg/5 mg/10 mg
NCT03322631 · Phase 1 · registry result, not featured evidence
0%5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%8mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%4.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%2.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%1.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%1mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%0.5mg
NCT02759107 · Phase 1 · registry result, not featured evidence
0%0.25mg
NCT02759107 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
15 mg once weeklya
nausea 22.5%
diarrhoea 21.9%
decreased appetite 10.4%
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 63 more results
10 mg once weekly
diarrhoea 19.8%
nausea 16.2%
decreased appetite 11%
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg once weekly
diarrhoea 12.5%
nausea 11.9%
decreased appetite 8.8%
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15 mg
nausea 27%
nasopharyngitis 18.2%
constipation 14.9%
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
constipation 13.6%
diarrhoea 13.6%
nasopharyngitis 13.6%
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
nasopharyngitis 18.9%
nausea 9.5%
constipation 8.1%
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
nausea 18.2% (placebo 6.1%)
diarrhoea 11.6% (placebo 7.8%)
decreased appetite 8.3% (placebo 0.9%)
NCT03954834 · Phase 3
10 mg
diarrhoea 14% (placebo 7.8%)
nausea 13.2% (placebo 6.1%)
decreased appetite 6.6% (placebo 0.9%)
NCT03954834 · Phase 3
5 mg
diarrhoea 11.6% (placebo 7.8%)
nausea 11.6% (placebo 6.1%)
dyspepsia 9.1% (placebo 3.5%)
NCT03954834 · Phase 3
15 mg weekly
nausea 22.1%
diarrhoea 13.8%
vomiting 9.8%
NCT03987919 · Phase 3
10 mg weekly
nausea 19.2%
diarrhoea 16.4%
vomiting 8.3%
NCT03987919 · Phase 3
5 mg weekly
nausea 17.4%
diarrhoea 13.2%
decreased appetite 7.4%
NCT03987919 · Phase 3
15 mg
nausea 23.7%
diarrhoea 15.6%
decreased appetite 12%
NCT03882970 · Phase 3
10 mg
nausea 22.5%
diarrhoea 16.4%
decreased appetite 10.3%
NCT03882970 · Phase 3
5 mg
diarrhoea 15.4%
nausea 11.5%
decreased appetite 6.1%
NCT03882970 · Phase 3
15 mg
diarrhoea 20.8% (placebo 10%)
nausea 18.3% (placebo 2.5%)
decreased appetite 14.2% (placebo 1.7%)
NCT04039503 · Phase 3
10 mg
nausea 17.6% (placebo 2.5%)
decreased appetite 12.6% (placebo 1.7%)
diarrhoea 12.6% (placebo 10%)
NCT04039503 · Phase 3
5 mg
nasopharyngitis 15.5% (placebo 19.2%)
nausea 12.9% (placebo 2.5%)
diarrhoea 12.1% (placebo 10%)
NCT04039503 · Phase 3
10 mg
nasopharyngitis 9.1% (placebo 5.9%)
vomiting 6.1% (placebo 2.9%)
diarrhoea 3% (placebo 5.9%)
NCT05260021 · Phase 3
10 mg
diarrhoea 24.2% (placebo 5.9%)
nausea 18.2% (placebo 8.8%)
abdominal pain upper 12.1% (placebo 8.8%)
NCT05260021 · Phase 3
5 mg
diarrhoea 25% (placebo 5.9%)
nausea 21.9% (placebo 8.8%)
abdominal pain 15.6% (placebo 2.9%)
NCT05260021 · Phase 3
5 mg
diarrhoea 15.6% (placebo 5.9%)
dysmenorrhoea 9.5% (placebo 0%)
headache 9.4% (placebo 2.9%)
NCT05260021 · Phase 3
MTD
nausea 25%
diarrhoea 24.7%
decreased appetite 17.1%
NCT04255433 · Phase 3
15 mg or MTD
nausea 25.2%
diarrhoea 22.3%
nasopharyngitis 10.1%
NCT05564039 · Phase 4 · registry result, not featured evidence
15 mg
diarrhoea 28.8% (placebo 0%)
decreased appetite 26.9% (placebo 0%)
nausea 26.9% (placebo 2%)
NCT05963022 · Phase 3 · registry result, not featured evidence
10 mg
decreased appetite 25.5% (placebo 0%)
diarrhoea 23.5% (placebo 0%)
nausea 21.6% (placebo 2%)
NCT05963022 · Phase 3 · registry result, not featured evidence
5 mg
decreased appetite 28.8% (placebo 0%)
diarrhoea 23.1% (placebo 0%)
upper respiratory tract infection 21.2% (placebo 19.6%)
NCT05963022 · Phase 3 · registry result, not featured evidence
15 mg
diarrhoea 36.5% (placebo 7.8%)
decreased appetite 31.7% (placebo 0%)
upper respiratory tract infection 17.5% (placebo 14.1%)
NCT05691712 · Phase 3 · registry result, not featured evidence
10 mg
diarrhoea 36.9% (placebo 7.8%)
decreased appetite 24.6% (placebo 0%)
lipase increased 21.5% (placebo 3.1%)
NCT05691712 · Phase 3 · registry result, not featured evidence
5 mg
decreased appetite 29.2% (placebo 0%)
diarrhoea 26.2% (placebo 7.8%)
upper respiratory tract infection 20% (placebo 14.1%)
NCT05691712 · Phase 3 · registry result, not featured evidence
15 mg
nausea 25.8%
decreased appetite 16.9%
vomiting 12.7%
NCT04537923 · Phase 3 · registry result, not featured evidence
10 mg
nausea 20.6%
diarrhoea 15.1%
decreased appetite 11.8%
NCT04537923 · Phase 3 · registry result, not featured evidence
5 mg
nausea 13.6%
diarrhoea 11.9%
covid-19 11.5%
NCT04537923 · Phase 3 · registry result, not featured evidence
15 mg
decreased appetite 44.5%
diarrhoea 44.1%
nausea 31.9%
NCT04093752 · Phase 3 · registry result, not featured evidence
10 mg
decreased appetite 47.8%
diarrhoea 45.2%
nausea 32.9%
NCT04093752 · Phase 3 · registry result, not featured evidence
5 mg
diarrhoea 33.5%
decreased appetite 32.2%
nausea 20%
NCT04093752 · Phase 3 · registry result, not featured evidence
15 mg
decreased appetite 21.9%
nausea 20%
constipation 13.8%
NCT03861052 · Phase 3 · registry result, not featured evidence
10 mg
nausea 19.6%
constipation 17.7%
nasopharyngitis 15.8%
NCT03861052 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 18.2%
diarrhoea 17%
constipation 15.1%
NCT03861052 · Phase 3 · registry result, not featured evidence
15 mg
nausea 39.6% (placebo 5.9%)
diarrhoea 32.1% (placebo 3.9%)
vomiting 26.4% (placebo 2%)
NCT03131687 · Phase 2 · registry result, not featured evidence
10 mg
decreased appetite 25.5% (placebo 2%)
diarrhoea 23.5% (placebo 3.9%)
nausea 21.6% (placebo 5.9%)
NCT03131687 · Phase 2 · registry result, not featured evidence
5 mg
diarrhoea 23.6% (placebo 3.9%)
decreased appetite 20% (placebo 2%)
nausea 20% (placebo 5.9%)
NCT03131687 · Phase 2 · registry result, not featured evidence
1 mg
diarrhoea 13.5% (placebo 3.9%)
dizziness 7.7% (placebo 3.9%)
decreased appetite 3.8% (placebo 2%)
NCT03131687 · Phase 2 · registry result, not featured evidence
nausea 39.3% (placebo 7.7%)
diarrhoea 35.7% (placebo 7.7%)
decreased appetite 21.4% (placebo 0%)
NCT03311724 · Phase 2 · registry result, not featured evidence
nausea 35.7% (placebo 7.7%)
diarrhoea 32.1% (placebo 7.7%)
decreased appetite 28.6% (placebo 0%)
NCT03311724 · Phase 2 · registry result, not featured evidence
diarrhoea 31% (placebo 7.7%)
nausea 24.1% (placebo 7.7%)
dyspepsia 17.2% (placebo 0%)
NCT03311724 · Phase 2 · registry result, not featured evidence
15 mg
nausea 38.5% (placebo 5.6%)
diarrhoea 17.9% (placebo 11.1%)
headache 17.9% (placebo 8.3%)
NCT04050553 · Phase 1 · registry result, not featured evidence
2.5 to 15 mg
decreased appetite 80% (placebo 0%)
abdominal distension 50% (placebo 0%)
diarrhoea 40% (placebo 0%)
NCT04235959 · Phase 1 · registry result, not featured evidence
2.5 to 10 mg
diarrhoea 60% (placebo 0%)
decreased appetite 50% (placebo 0%)
hyperlipidaemia 50% (placebo 75%)
NCT04235959 · Phase 1 · registry result, not featured evidence
15 mg
decreased appetite 60% (placebo 25%)
early satiety 35.6% (placebo 21.4%)
injection site haematoma 26.7% (placebo 42.9%)
NCT03951753 · Phase 1 · registry result, not featured evidence
5 mg
decreased appetite 45.5% (placebo 0%)
abdominal distension 27.3% (placebo 11.1%)
malaise 9.1% (placebo 0%)
NCT03322631 · Phase 1 · registry result, not featured evidence
5 mg/10 mg/15 mg
decreased appetite 62.5% (placebo 0%)
constipation 50% (placebo 11.1%)
diarrhoea 31.3% (placebo 0%)
NCT03322631 · Phase 1 · registry result, not featured evidence
2.5 mg/5 mg/10 mg
constipation 66.7% (placebo 11.1%)
decreased appetite 50% (placebo 0%)
diarrhoea 25% (placebo 0%)
NCT03322631 · Phase 1 · registry result, not featured evidence
5mg
decreased appetite 66.7% (placebo 7.1%)
abdominal distension 50% (placebo 7.1%)
catheter site erythema 33.3% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence
5mg
decreased appetite 66.7% (placebo 7.1%)
abdominal distension 11.1% (placebo 7.1%)
catheter site bruise 11.1% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence
8mg
decreased appetite 85.7% (placebo 7.1%)
nausea 57.1% (placebo 0%)
vomiting 42.9% (placebo 0%)
NCT02759107 · Phase 1 · registry result, not featured evidence
4.5mg
decreased appetite 83.3% (placebo 7.1%)
abdominal distension 66.7% (placebo 7.1%)
dizziness 33.3% (placebo 0%)
NCT02759107 · Phase 1 · registry result, not featured evidence
2.5mg
abdominal distension 16.7% (placebo 7.1%)
catheter site erythema 16.7% (placebo 7.1%)
nausea 16.7% (placebo 0%)
NCT02759107 · Phase 1 · registry result, not featured evidence
1.5mg
catheter site erythema 16.7% (placebo 7.1%)
cough 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence
1mg
application site erythema 20% (placebo 0%)
catheter site bruise 20% (placebo 7.1%)
dermatitis contact 20% (placebo 0%)
NCT02759107 · Phase 1 · registry result, not featured evidence
0.5mg
upper respiratory tract infection 33.3% (placebo 14.3%)
vessel puncture site bruise 33.3% (placebo 0%)
injection site pain 25% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence
0.5mg
application site erythema 33.3% (placebo 0%)
medical device site pruritus 33.3% (placebo 0%)
abdominal distension 16.7% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence
0.5mg
decreased appetite 22.2% (placebo 7.1%)
upper respiratory tract infection 22.2% (placebo 14.3%)
hysterectomy 16.7% (placebo 0%)
NCT02759107 · Phase 1 · registry result, not featured evidence
0.25mg
catheter site bruise 16.7% (placebo 7.1%)
catheter site swelling 16.7% (placebo 7.1%)
injection site pain 16.7% (placebo 7.1%)
NCT02759107 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 60 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tirzepatide (Mounjaro)

HbA1c -2.58% (n=291) vs -1.44% (n=887) Insulin Glargine @ 52wk15 mg once weekly
absolute change · percentage points
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 50 more results
-2.07% (n=116) vs 0.04% (n=112) placebo @ 40wk15 mg
NCT03954834 · Phase 3
-2.46% (n=464) vs -1.86% (n=461) Semaglutide @ 40wk15 mg weekly
NCT03987919 · Phase 3
-2.37% (n=294) vs -1.34% (n=317) Insulin Degludec @ 52wk15 mg
NCT03882970 · Phase 3
-2.59% (n=117) vs -0.93% (n=118) placebo @ 40wk15 mg
NCT04039503 · Phase 3
-1.59% (n=114) vs -0.69% (n=105) Dulaglutide @ 40wk15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
-2.03% (n=48) vs -0.77% (n=47) placebo @ 40wk15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-2.46% (n=233) vs -1.16% (n=692) Insulin Lispro @ 52wk15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-2.49% (n=193) vs -0.95% (n=193) Insulin Glargine @ 40wk15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-2.82% (n=159) vs -1.29% (n=159) Dulaglutide @ 52wk15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-1.94% (n=44) vs -0.06% (n=44) placebo @ 26wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.72% (n=48) vs -0.05% (n=48) placebo @ 12wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2.4% (n=35) vs 0.1% (n=41) placebo @ 26wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2.1% (n=36) vs -0.1% (n=44) placebo @ 12wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2% (n=23) vs 0.2% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
-1.8% (n=26) vs 0.2% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
2.05% (n=41) vs 0.29% (n=24) placebo @ 28wk15 mg
NCT03951753 · Phase 1 · registry result, not featured evidence
-2.43% (n=289) vs -1.44% (n=887) Insulin Glargine @ 52wk10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.89% (n=118) vs 0.04% (n=112) placebo @ 40wk10 mg
NCT03954834 · Phase 3
-2.37% (n=459) vs -1.86% (n=461) Semaglutide @ 40wk10 mg weekly
NCT03987919 · Phase 3
-2.2% (n=291) vs -1.34% (n=317) Insulin Degludec @ 52wk10 mg
NCT03882970 · Phase 3
-2.59% (n=113) vs -0.93% (n=118) placebo @ 40wk10 mg
NCT04039503 · Phase 3
-2.16% (n=27) vs -0.23% (n=32) placebo @ 30wk10 mg
NCT05260021 · Phase 3
-1.75% (n=44) vs -0.77% (n=47) placebo @ 40wk10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-2.27% (n=234) vs -1.16% (n=692) Insulin Lispro @ 52wk10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-2.44% (n=194) vs -0.95% (n=193) Insulin Glargine @ 40wk10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-2.55% (n=156) vs -1.29% (n=159) Dulaglutide @ 52wk10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-1.89% (n=47) vs -0.06% (n=44) placebo @ 26wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.68% (n=48) vs -0.05% (n=48) placebo @ 12wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2% (n=43) vs 0.1% (n=41) placebo @ 26wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2% (n=47) vs -0.1% (n=44) placebo @ 12wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-2.24% (n=283) vs -1.44% (n=887) Insulin Glargine @ 52wk5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.87% (n=121) vs 0.04% (n=112) placebo @ 40wk5 mg
NCT03954834 · Phase 3
-2.09% (n=461) vs -1.86% (n=461) Semaglutide @ 40wk5 mg weekly
NCT03987919 · Phase 3
-1.93% (n=312) vs -1.34% (n=317) Insulin Degludec @ 52wk5 mg
NCT03882970 · Phase 3
-2.23% (n=115) vs -0.93% (n=118) placebo @ 40wk5 mg
NCT04039503 · Phase 3
-1.9% (n=29) vs -0.23% (n=32) placebo @ 30wk5 mg
NCT05260021 · Phase 3
-2.19% (n=52) vs -0.77% (n=47) placebo @ 40wk5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-2.05% (n=241) vs -1.16% (n=692) Insulin Lispro @ 52wk5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-2.24% (n=211) vs -0.95% (n=193) Insulin Glargine @ 40wk5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-2.37% (n=158) vs -1.29% (n=159) Dulaglutide @ 52wk5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-1.73% (n=52) vs -0.06% (n=44) placebo @ 26wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.54% (n=52) vs -0.05% (n=48) placebo @ 12wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.6% (n=47) vs 0.1% (n=41) placebo @ 26wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.7% (n=49) vs -0.1% (n=44) placebo @ 12wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.7% (n=27) vs 0.2% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
-1.06% (n=45) vs -0.06% (n=44) placebo @ 26wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-0.94% (n=45) vs -0.05% (n=48) placebo @ 12wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-0.7% (n=44) vs 0.1% (n=41) placebo @ 26wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-0.9% (n=44) vs -0.1% (n=44) placebo @ 12wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-1.66% (n=6586) vs -0.88% (n=6579) Dulaglutide @ 156wkMTD
NCT04255433 · Phase 3
Weight -11.7 vs 1.9 Insulin Glargine kg @ 52wk15 mg once weekly
absolute change · kg
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 37 more results
-9.5 vs -0.7 placebo kg @ 40wk15 mg
NCT03954834 · Phase 3
-12.4 vs -6.2 Semaglutide kg @ 40wk15 mg weekly
NCT03987919 · Phase 3
-12.9 vs 2.3 Insulin Degludec kg @ 52wk15 mg
NCT03882970 · Phase 3
-10.9 vs 1.7 placebo kg @ 40wk15 mg
NCT04039503 · Phase 3
-11 vs -3.6 Dulaglutide kg @ 40wk15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
-8.7 vs -1.3 placebo kg @ 40wk15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-4.3 vs 1.7 placebo kg @ 40wk15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-12 vs 3.8 Insulin Lispro kg @ 52wk15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-7.2 vs 1.5 Insulin Glargine kg @ 40wk15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-10.7 vs -0.5 Dulaglutide kg @ 52wk15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-11.3 vs -0.4 placebo kg @ 26wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-5.5 vs -0.5 placebo kg @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
-5.7 vs -0.5 placebo kg @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
-9.5 vs 1.9 Insulin Glargine kg @ 52wk10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-7.8 vs -0.7 placebo kg @ 40wk10 mg
NCT03954834 · Phase 3
-10.3 vs -6.2 Semaglutide kg @ 40wk10 mg weekly
NCT03987919 · Phase 3
-10.7 vs 2.3 Insulin Degludec kg @ 52wk10 mg
NCT03882970 · Phase 3
-8.2 vs 1.7 placebo kg @ 40wk10 mg
NCT04039503 · Phase 3
-5.5 vs -1.3 placebo kg @ 40wk10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-4.8 vs 1.7 placebo kg @ 40wk10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-9.9 vs 3.8 Insulin Lispro kg @ 52wk10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-7 vs 1.5 Insulin Glargine kg @ 40wk10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-8.5 vs -0.5 Dulaglutide kg @ 52wk10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-8.7 vs -0.4 placebo kg @ 26wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-7.1 vs 1.9 Insulin Glargine kg @ 52wk5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-7 vs -0.7 placebo kg @ 40wk5 mg
NCT03954834 · Phase 3
-7.8 vs -6.2 Semaglutide kg @ 40wk5 mg weekly
NCT03987919 · Phase 3
-7.5 vs 2.3 Insulin Degludec kg @ 52wk5 mg
NCT03882970 · Phase 3
-6.2 vs 1.7 placebo kg @ 40wk5 mg
NCT04039503 · Phase 3
-6.1 vs -1.3 placebo kg @ 40wk5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-2.7 vs 1.7 placebo kg @ 40wk5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-6.9 vs 3.8 Insulin Lispro kg @ 52wk5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-5 vs 1.5 Insulin Glargine kg @ 40wk5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-5.8 vs -0.5 Dulaglutide kg @ 52wk5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-4.8 vs -0.4 placebo kg @ 26wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
-5.3 vs -0.5 placebo kg @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
-0.9 vs -0.4 placebo kg @ 26wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 7% 90.72% (n=334) vs 50.72% (n=978) Insulin Glargine @ 52wk15 mg once weekly
responder rate · % of participants
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 36 more results
87.93% (n=116) vs 19.64% (n=112) placebo @ 40wk15 mg
NCT03954834 · Phase 3
92.24% (n=464) vs 81.13% (n=461) Semaglutide @ 40wk15 mg weekly
NCT03987919 · Phase 3
92.63% (n=353) vs 61.25% (n=351) Insulin Degludec @ 52wk15 mg
NCT03882970 · Phase 3
94.02% (n=117) vs 33.9% (n=118) placebo @ 40wk15 mg
NCT04039503 · Phase 3
84.21% (n=114) vs 52.38% (n=105) Dulaglutide @ 40wk15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
83.33% (n=48) vs 38.3% (n=47) placebo @ 40wk15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
79.86% (n=236) vs 36.69% (n=708) Insulin Lispro @ 52wk15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
84.38% (n=224) vs 23.72% (n=215) Insulin Glargine @ 40wk15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
99.37% (n=159) vs 67.3% (n=159) Dulaglutide @ 52wk15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
77.4% (n=53) vs 11.8% (n=51) placebo @ 26wk15 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
87% (n=23) vs 10% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
84.6% (n=26) vs 10% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
88.16% (n=321) vs 50.72% (n=978) Insulin Glargine @ 52wk10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
91.53% (n=118) vs 19.64% (n=112) placebo @ 40wk10 mg
NCT03954834 · Phase 3
88.89% (n=459) vs 81.13% (n=461) Semaglutide @ 40wk10 mg weekly
NCT03987919 · Phase 3
89.71% (n=350) vs 61.25% (n=351) Insulin Degludec @ 52wk10 mg
NCT03882970 · Phase 3
97.35% (n=113) vs 33.9% (n=118) placebo @ 40wk10 mg
NCT04039503 · Phase 3
84.5% (n=33) vs 37.4% (n=34) placebo @ 30wk10 mg
NCT05260021 · Phase 3
86.36% (n=44) vs 38.3% (n=47) placebo @ 40wk10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
75.64% (n=238) vs 36.69% (n=708) Insulin Lispro @ 52wk10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
86.04% (n=222) vs 23.72% (n=215) Insulin Glargine @ 40wk10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
96.79% (n=156) vs 67.3% (n=159) Dulaglutide @ 52wk10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
90% (n=50) vs 11.8% (n=51) placebo @ 26wk10 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
80.98% (n=326) vs 50.72% (n=978) Insulin Glargine @ 52wk5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
86.78% (n=121) vs 19.64% (n=112) placebo @ 40wk5 mg
NCT03954834 · Phase 3
85.47% (n=461) vs 81.13% (n=461) Semaglutide @ 40wk5 mg weekly
NCT03987919 · Phase 3
82.44% (n=353) vs 61.25% (n=351) Insulin Degludec @ 52wk5 mg
NCT03882970 · Phase 3
93.04% (n=115) vs 33.9% (n=118) placebo @ 40wk5 mg
NCT04039503 · Phase 3
79.6% (n=32) vs 37.4% (n=34) placebo @ 30wk5 mg
NCT05260021 · Phase 3
90.38% (n=52) vs 38.3% (n=47) placebo @ 40wk5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
61.04% (n=242) vs 36.69% (n=708) Insulin Lispro @ 52wk5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
75.44% (n=228) vs 23.72% (n=215) Insulin Glargine @ 40wk5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
93.67% (n=158) vs 67.3% (n=159) Dulaglutide @ 52wk5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
69.1% (n=55) vs 11.8% (n=51) placebo @ 26wk5 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
74.1% (n=27) vs 10% (n=20) placebo @ 12wk
NCT03311724 · Phase 2 · registry result, not featured evidence
32.7% (n=52) vs 11.8% (n=51) placebo @ 26wk1 mg
NCT03131687 · Phase 2 · registry result, not featured evidence
Fasting Glucose Change mg/dL -59.3 vs -51.4 Insulin Glargine mg @ 52wk15 mg once weekly
absolute change · mg
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
-51.4 vs -4.3 placebo mg @ 28wk15 mg
NCT03951753 · Phase 1 · registry result, not featured evidence
-54.9 vs -51.4 Insulin Glargine mg @ 52wk10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-50.4 vs -51.4 Insulin Glargine mg @ 52wk5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
SMBG Daily Average Change mg/dL -66.1 vs -46.1 Insulin Glargine mg/dL @ 52wk15 mg once weekly
absolute change · mg/dL
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 14 more results
-74.3 vs -61.4 Semaglutide mg/dL @ 40wk15 mg weekly
NCT03987919 · Phase 3
-60.6 vs -48 Insulin Degludec mg/dL @ 52wk15 mg
NCT03882970 · Phase 3
-73.7 vs -39.4 placebo mg/dL @ 40wk15 mg
NCT04039503 · Phase 3
-68.6 vs -42.2 Dulaglutide mg/dL @ 52wk15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-61.1 vs -46.1 Insulin Glargine mg/dL @ 52wk10 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-70.6 vs -61.4 Semaglutide mg/dL @ 40wk10 mg weekly
NCT03987919 · Phase 3
-59.7 vs -48 Insulin Degludec mg/dL @ 52wk10 mg
NCT03882970 · Phase 3
-71.7 vs -39.4 placebo mg/dL @ 40wk10 mg
NCT04039503 · Phase 3
-64.2 vs -42.2 Dulaglutide mg/dL @ 52wk10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-58.4 vs -46.1 Insulin Glargine mg/dL @ 52wk5 mg once weekly
NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-65.4 vs -61.4 Semaglutide mg/dL @ 40wk5 mg weekly
NCT03987919 · Phase 3
-52.6 vs -48 Insulin Degludec mg/dL @ 52wk5 mg
NCT03882970 · Phase 3
-67.1 vs -39.4 placebo mg/dL @ 40wk5 mg
NCT04039503 · Phase 3
-59.5 vs -42.2 Dulaglutide mg/dL @ 52wk5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
HbA1c -3.02% (n=145) @ 52wk15 mg
absolute change · percentage points
No placebo or comparator arm
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-2.98% (n=146) @ 52wk10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.57% (n=148) @ 52wk5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=140) @ 12wk5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 96.55% (n=145) @ 52wk15 mg
responder rate · % of participants
No placebo or comparator arm
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
97.95% (n=146) @ 52wk10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
92.57% (n=148) @ 52wk5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Serum Glucose Change mg/dL -74.4 mg @ 52wk15 mg
absolute change · mg
No placebo or comparator arm
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-71.2 mg @ 52wk10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-58.6 mg @ 52wk5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7.83 mg @ 12wk5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
Weight -10.2 kg @ 52wk15 mg
absolute change · kg
No placebo or comparator arm
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-7.5 kg @ 52wk10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.8 kg @ 52wk5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.15 kg @ 12wk5 mg
NCT05706506 · Phase 4 · registry result, not featured evidence
Weight Loss 5% 84.14% (n=145) @ 52wk15 mg
responder rate · % of participants
No placebo or comparator arm
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
70.55% (n=146) @ 52wk10 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
43.92% (n=148) @ 52wk5 mg
NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Serum Glucose Change mg/dL -49.3 vs 12.9 placebo mg @ 40wk15 mg
absolute change · mg
NCT03954834 · Phase 3
show 28 more results
-63.4 vs -48.6 Semaglutide mg @ 40wk15 mg weekly
NCT03987919 · Phase 3
-59.2 vs -55.7 Insulin Degludec mg @ 52wk15 mg
NCT03882970 · Phase 3
-67.7 vs -38.9 placebo mg @ 40wk15 mg
NCT04039503 · Phase 3
-55.4 vs -30.2 placebo mg @ 40wk15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-51 vs -23.7 placebo mg @ 40wk15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-41.6 vs -10 Insulin Lispro mg @ 52wk15 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-64.8 vs -46.2 Insulin Glargine mg @ 40wk15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-67.6 vs -31.9 Dulaglutide mg @ 52wk15 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-45.9 vs 12.9 placebo mg @ 40wk10 mg
NCT03954834 · Phase 3
-61.6 vs -48.6 Semaglutide mg @ 40wk10 mg weekly
NCT03987919 · Phase 3
-54.8 vs -55.7 Insulin Degludec mg @ 52wk10 mg
NCT03882970 · Phase 3
-67.9 vs -38.9 placebo mg @ 40wk10 mg
NCT04039503 · Phase 3
-50.6 vs -6.6 placebo mg @ 30wk10 mg
NCT05260021 · Phase 3
-54.8 vs -30.2 placebo mg @ 40wk10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-52.5 vs -23.7 placebo mg @ 40wk10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-43 vs -10 Insulin Lispro mg @ 52wk10 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-66.2 vs -46.2 Insulin Glargine mg @ 40wk10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-64.6 vs -31.9 Dulaglutide mg @ 52wk10 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
-43.6 vs 12.9 placebo mg @ 40wk5 mg
NCT03954834 · Phase 3
-56 vs -48.6 Semaglutide mg @ 40wk5 mg weekly
NCT03987919 · Phase 3
-48.2 vs -55.7 Insulin Degludec mg @ 52wk5 mg
NCT03882970 · Phase 3
-61.4 vs -38.9 placebo mg @ 40wk5 mg
NCT04039503 · Phase 3
-35.5 vs -6.6 placebo mg @ 30wk5 mg
NCT05260021 · Phase 3
-55 vs -30.2 placebo mg @ 40wk5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
-45.5 vs -23.7 placebo mg @ 40wk5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
-33.2 vs -10 Insulin Lispro mg @ 52wk5 mg
NCT04537923 · Phase 3 · registry result, not featured evidence
-58.6 vs -46.2 Insulin Glargine mg @ 40wk5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
-57.9 vs -31.9 Dulaglutide mg @ 52wk5 mg
NCT03861052 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 5 7 51.72% (n=116) vs 0.89% (n=112) placebo @ 40wk15 mg
responder rate · % of participants
NCT03954834 · Phase 3
show 20 more results
50.86% (n=464) vs 19.74% (n=461) Semaglutide @ 40wk15 mg weekly
NCT03987919 · Phase 3
62.39% (n=117) vs 2.54% (n=118) placebo @ 40wk15 mg
NCT04039503 · Phase 3
21.64% (n=134) vs 2.27% (n=132) Dulaglutide @ 40wk15 mg or MTD
NCT05564039 · Phase 4 · registry result, not featured evidence
56.25% (n=48) vs 0% (n=47) placebo @ 40wk15 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
25.45% (n=55) vs 0% (n=58) placebo @ 40wk15 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
27.68% (n=224) vs 0% (n=215) Insulin Glargine @ 40wk15 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
30.51% (n=118) vs 0.89% (n=112) placebo @ 40wk10 mg
NCT03954834 · Phase 3
44.66% (n=459) vs 19.74% (n=461) Semaglutide @ 40wk10 mg weekly
NCT03987919 · Phase 3
47.79% (n=113) vs 2.54% (n=118) placebo @ 40wk10 mg
NCT04039503 · Phase 3
56.2% (n=33) vs 15.9% (n=34) placebo @ 30wk10 mg
NCT05260021 · Phase 3
34.09% (n=44) vs 0% (n=47) placebo @ 40wk10 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
17.54% (n=57) vs 0% (n=58) placebo @ 40wk10 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
20.72% (n=222) vs 0% (n=215) Insulin Glargine @ 40wk10 mg
NCT04093752 · Phase 3 · registry result, not featured evidence
33.88% (n=121) vs 0.89% (n=112) placebo @ 40wk5 mg
NCT03954834 · Phase 3
29.28% (n=461) vs 19.74% (n=461) Semaglutide @ 40wk5 mg weekly
NCT03987919 · Phase 3
26.09% (n=115) vs 2.54% (n=118) placebo @ 40wk5 mg
NCT04039503 · Phase 3
44.1% (n=32) vs 15.9% (n=34) placebo @ 30wk5 mg
NCT05260021 · Phase 3
40.38% (n=52) vs 0% (n=47) placebo @ 40wk5 mg
NCT05963022 · Phase 3 · registry result, not featured evidence
9.68% (n=62) vs 0% (n=58) placebo @ 40wk5 mg
NCT05691712 · Phase 3 · registry result, not featured evidence
14.91% (n=228) vs 0% (n=215) Insulin Glargine @ 40wk5 mg
NCT04093752 · Phase 3 · registry result, not featured evidence

+ 46 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ribupatide's landscape · Tirzepatide (Mounjaro)'s landscape